Saturday 17 October 2026
Export INBX’s income statement to Excel — free account
Inhibrx Biosciences, Inc.
INBX Healthcare Biotechnology
Inhibrx Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.3 million, up 550.0% from fiscal 2024. In the quarter to June 2026, revenue grew 992.4%, EPS fell 26.5%, free cash flow was flat and total debt rose 77.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
89.83
0.67
−0.74%
Follow INBX
| Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|
Piotroski F-Score |
— | — | 3 | 2 |
P/E ratio |
0.00 | 0.00 | 0.13 | 0.00 |
Altman Z-Score |
— | — | (3.18) | 0.73 |
P/S ratio |
0.00 | 0.00 | 115.71 | 388.28 |
Altman Z″-Score (non-manufacturers) |
— | (6.02) | (6.92) | (7.18) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 |
Beneish M-Score |
— | (2.00) | 43.81 | 0.31 |
P/Operating CF |
(2.71) | (2.71) | (5.21) | (40.62) |
P/B ratio |
0.00 | 0.00 | 1.71 | 153.07 |
Price to Tangible BV |
0.00 | 0.00 | 1.71 | 153.07 |
EV/Sales |
0.00 | 0.00 | 143.31 | 380.77 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(0.60) | (0.60) | (1.45) | (9.24) |
EV/FCF |
(0.58) | (0.58) | (1.43) | (9.24) |
Quick Ratio |
0.01 | 4.95 | 3.76 | 3.68 |
Current Ratio |
0.30 | 5.25 | 3.94 | 3.93 |
Net Debt/EBITDA |
0.00 | 0.33 | 0.46 | 0.18 |
Debt/Assets |
0.00% | 67.22% | 0.00% | 68.65% |
Debt/Equity |
0.00 | 4.76 | 0.00 | 12.58 |
Asset Turnover |
0.00 | 0.01 | 0.00 | 0.01 |
Operating CF/Net income |
0.79 | 0.80 | (0.12) | 0.93 |
Capex/Depreciation |
(0.56) | (3.86) | (1.14) | (0.01) |
Interest Coverage |
— | (6.89) | (24.57) | (11.07) |
| 0.00% | (1,333.38%) | 1,905.92% | (197.85%) | |
| 0.00% | (148.74%) | 690.69% | (85.60%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
960.40% | (98.33%) | 1,340.75% | (136.29%) |
Average Days of Receivables |
71.33 | 157.76 | 766.50 | 49.70 |
Research and Development Expense of Revenue |
7,726.46% | 10,646.67% | 101,871.50% | 8,694.46% |
Selling, General and Administrative Expense of Revenue |
1,143.35% | 1,632.28% | 63,952.50% | 1,792.08% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
1,352.93% | 1,380.33% | 29,259.00% | 856.77% |
Graham Net Nets |
(0.15) | (0.15) | 0.50 | 0.00 |
Graham Number |
0.00 | 0.00 | 153.08 | 0.00 |
Earnings Yield |
(209.87%) | (209.87%) | 749.34% | (11.44%) |
Free Cash Flow Yield |
(100.11%) | (100.11%) | (86.42%) | (10.61%) |
Revenue per Share |
0.00 | 0.15 | 0.01 | 0.08 |
Operating CF per Share |
0.00 | (16.41) | (13.13) | (8.38) |
Capex per Share |
0.00 | (0.39) | (0.18) | 0.00 |
Free Cash Flow per Share |
0.00 | (16.80) | (13.31) | (8.38) |
Cash per Share |
— | 23.59 | 10.31 | 8.02 |
Shareholders Equity per Share |
0.00 | 3.69 | 9.02 | 0.52 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.00 | 3.69 | 9.02 | 0.52 |
Free Cash Flow |
(91.50) | (197.90) | (197.01) | (129.82) |
Working Capital |
(14.51) | 239.05 | 119.67 | 99.03 |
Capital Expenditures |
(0.69) | (4.59) | (2.60) | (0.03) |
Net Current Asset Value |
(17.68) | 30.97 | 113.22 | (5.65) |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.52 | 2.55 | 12.99 | 0.02 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||
Depreciation/Fixed assets |
0.49 | 0.19 | 0.37 | 0.67 |
Cash ROIC |
1,253.38% | (37.45%) | (68.84%) | (55.77%) |
Accounts Receivable Turnover |
0.00 | 3.48 | 0.33 | 4.36 |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
— | 0.52 | 0.60 | 0.30 |
Average Payables |
— | 7.65 | 10.10 | 7.59 |
Average Assets |
— | 162.27 | 244.33 | 163.62 |
Average Common Equity |
— | 18.10 | 88.54 | 70.79 |
Columns are period end dates